Moderna and Merck's personalized cancer vaccines have added more than $50 billion in combined market value for the two drugmakers. The vaccines depend on genetic sequencing to identify the mutations each patient's immune system should target. That sequencing step could become a recurring revenue stream for Tempus AI, the genomic-sequencing firm lined up as the partner if the vaccine wins regulatory approval.
The Sequencing Opportunity
Tempus AI's role is straightforward: sequence a patient's tumor, find the mutations, and feed that data into the vaccine design. Analysts see this as a per-patient service that repeats with each new patient, not a one-time deal. Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million in annual sequencing revenue if regulators approve it. BTIG's Mark Massaro goes further, projecting that figure could exceed $600 million assuming the vaccine expands into lung, bladder, and kidney cancers. "That opportunity is barely reflected in Tempus AI's stock today," Massaro said.
The math is simple. Each patient needs a unique vaccine, which means a unique sequencing run. That's a recurring, per-patient revenue stream. And if the vaccine works, the patient pool grows. Massaro's $600 million figure assumes the vaccine moves beyond melanoma into other solid tumors. That's a big if, but it's the kind of upside that gets investors' attention.
MRD Testing: The Bigger Prize
The sequencing work might be just the entry point. The larger opportunity, investors say, is minimal residual disease (MRD) testing, which monitors for cancer recurrence and could bring patients back for years. Bioaxia CEO Douglas Eby sees the sequencing step as a customer-acquisition funnel, with MRD testing as the recurring revenue source. Investors view MRD testing as a multibillion-dollar market. Natera currently controls most of it, with a valuation near $45 billion.
The idea is that a patient who gets a vaccine will need ongoing monitoring. MRD tests can catch a recurrence early, and that's a service patients might use for years. For Tempus AI, the sequencing is the hook; the MRD testing is the long-term relationship. That's why investors are watching this space so closely.
Risks and Competition
The mRNA cancer-vaccine space remains unproven. BioNTech recently suffered a setback in a mid-stage colorectal cancer vaccine trial, a reminder that success isn't guaranteed. There's also the possibility that pharmaceutical companies eventually handle some sequencing in-house or split the work among competing diagnostic labs. That could reduce the share Tempus AI gets, even if the vaccine succeeds.
The regulatory path is also uncertain. The Moderna-Merck vaccine is still in trials, and approval isn't a given. If it fails, the sequencing opportunity evaporates. If it succeeds, Tempus AI could be in a strong position, but competition could erode that advantage.
The next step is regulatory approval for the Moderna-Merck vaccine. If it comes through, Tempus AI's sequencing role becomes concrete. Until then, the $600 million projection is just that — a projection.
